Our study provides valuable insights for the development of a therapeutic approach combining anti-IL-17A or anti-CXCL16 neutralizing antibodies with the TKI imatinib to achieve complete remission of Ph+ B-ALL. This evidence concerns the gene IL17A and acute lymphoblastic leukemia.